Skip to main content
. 2019 Jun 12;14(6):e0217572. doi: 10.1371/journal.pone.0217572

Fig 3. A high level of platelets in peripheral blood prior to MSC administration among GvHD patients who responded to therapy.

Fig 3

Platelet levels prior to therapy in patients who responded to MSC therapy versus patients who did not respond (p = 0.01).